Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

0.6591 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 
From Athira Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
From Athira Pharma, Inc.
Via GlobeNewswire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Trade Gap Widens In July
Via Benzinga
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's treatment fosgonimeton, with data showing directional improvements but no... 
Via Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024 
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024 
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
From Athira Pharma, Inc.
Via GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization 
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease 
From Athira Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and... 
From Athira Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.